SEARCH

SEARCH BY CITATION

References

  • 1
    Koboldt D, Fulton C, McLellan RS, Schmidt MD, Kalicki-Veizer H, McMichael J, Fulton JF, Dooling LL, Ding DJ, Mardis L, et al. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490, 6170.
  • 2
    Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646674.
  • 3
    Passarino G, Cavalleri GL, Stecconi R, Franceschi C, Altomare K, Dato S, Greco V, Luca Cavalli Sforza L, Underhill PA & de Benedictis G (2003) Molecular variation of human HSP90alpha and HSP90beta genes in Caucasians. Hum Mutat 21, 554555.
  • 4
    Urban JD, Budinsky RA & Rowlands JC (2012) An evaluation of single nucleotide polymorphisms in the human heat shock protein 90 kDa alpha and beta isoforms. Drug Metab Pharmacokinet 27, 268278.
  • 5
    Komarova NL & Wodarz D (2005) Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci USA 102, 97149719.
  • 6
    Bozic I, Allen B & Nowak MA (2012) Dynamics of targeted cancer therapy. Trends Mol Med 18, 311316.
  • 7
    Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG & Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73.
  • 8
    Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, et al. (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11, 475484.
  • 9
    Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, et al. (2012) Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs 30, 22012209.
  • 10
    Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, Zhang C, Wada Y & Proia DA (2012) Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 11, 26332643.
  • 11
    Wiech H, Buchner J, Zimmermann R & Jakob U (1992) Hsp90 chaperones protein folding in vitro. Nature 358, 169170.
  • 12
    Pearl LH & Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75, 271294.
  • 13
    Sawarkar R, Sievers C & Paro R (2012) Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. Cell 149, 807818.
  • 14
    Mollapour M & Neckers L (2012) Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta 1823, 648655.
  • 15
    Owens-Grillo JK, Stancato LF, Hoffmann K, Pratt WB & Krishna P (1996) Binding of immunophilins to the 90 kDa heat shock protein (hsp90) via a tetratricopeptide repeat domain is a conserved protein interaction in plants. Biochemistry 35, 1524915255.
  • 16
    Ratajczak T & Carrello A (1996) Cyclophilin 40 (CyP-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding. J Biol Chem 271, 29612965.
  • 17
    Young JC, Obermann WM & Hartl FU (1998) Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90. J Biol Chem 273, 1800718010.
  • 18
    Chen S, Sullivan WP, Toft DO & Smith DF (1998) Differential interactions of p23 and the TPR-containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress Chaperones 3, 118129.
  • 19
    Smith DF, Baggenstoss BA, Marion TN & Rimerman RA (1993) Two FKBP-related proteins are associated with progesterone receptor complexes. J Biol Chem 268, 1836518371.
  • 20
    Silverstein AM, Galigniana MD, Chen MS, Owens-Grillo JK, Chinkers M & Pratt WB (1997) Protein phosphatase 5 is a major component of glucocorticoid receptor.hsp90 complexes with properties of an FK506-binding immunophilin. J Biol Chem 272, 1622416230.
  • 21
    Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Hohfeld J & Patterson C (2001) CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem 276, 4293842944.
  • 22
    Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, Millson SH, Clarke PA, Naaby-Hansen S, Stein R, et al. (2002) Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 10, 13071318.
  • 23
    Lotz GP, Lin H, Harst A & Obermann WM (2003) Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem 278, 1722817235.
  • 24
    Gray PJ Jr, Prince T, Cheng J, Stevenson MA & Calderwood SK (2008) Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer 8, 491495.
  • 25
    Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI & Lindquist S (2012) Quantitative analysis of hsp90–client interactions reveals principles of substrate recognition. Cell 150, 9871001.
  • 26
    Johnson JL & Toft DO (1994) A novel chaperone complex for steroid receptors involving heat shock proteins, immunophilins, and p23. J Biol Chem 269, 2498924993.
  • 27
    Johnson JL & Toft DO (1995) Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol Endocrinol 9, 670678.
  • 28
    Cox MB & Miller CA III (2004) Cooperation of heat shock protein 90 and p23 in aryl hydrocarbon receptor signaling. Cell Stress Chaperones 9, 420.
  • 29
    Forsythe HL, Jarvis JL, Turner JW, Elmore LW & Holt SE (2001) Stable association of hsp90 and p23, but not hsp70, with active human telomerase. J Biol Chem 276, 1557115574.
  • 30
    Trinklein ND, Chen WC, Kingston RE & Myers RM (2004) Transcriptional regulation and binding of heat shock factor 1 and heat shock factor 2 to 32 human heat shock genes during thermal stress and differentiation. Cell Stress Chaperones 9, 2128.
  • 31
    Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ & Whitesell L (2000) Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 6, 33123318.
  • 32
    Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB & Toft DO (2000) The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 275, 33053312.
  • 33
    Tsutsumi S, Mollapour M, Graf C, Lee CT, Scroggins BT, Xu W, Haslerova L, Hessling M, Konstantinova AA, Trepel JB, et al. (2009) Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nat Struct Mol Biol 16, 11411147.
  • 34
    Dollins DE, Warren JJ, Immormino RM & Gewirth DT (2007) Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol Cell 28, 4156.
  • 35
    Frey S, Leskovar A, Reinstein J & Buchner J (2007) The ATPase cycle of the endoplasmic chaperone Grp94. J Biol Chem 282, 3561235620.
  • 36
    Leskovar A, Wegele H, Werbeck ND, Buchner J & Reinstein J (2008) The ATPase cycle of the mitochondrial Hsp90 analog Trap1. J Biol Chem 283, 1167711688.
  • 37
    Chiosis G & Neckers L (2006) Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 1, 279284.
  • 38
    Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen AB, Mittlboeck M, Christensen JG, Rosen N, et al. (2011) Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition. Clin Cancer Res 17, 122133.
  • 39
    Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, et al. (2008) SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14, 240248.
  • 40
    Huang KH, Veal JM, Fadden RP, Rice JW, Eaves J, Strachan JP, Barabasz AF, Foley BE, Barta TE, Ma W, et al. (2009) Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52, 42884305.
  • 41
    Fadden P, Huang KH, Veal JM, Steed PM, Barabasz AF, Foley B, Hu M, Partridge JM, Rice J, Scott A, et al. (2010) Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol 17, 686694.
  • 42
    Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM & Egorin MJ (2005) Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 55, 2132.
  • 43
    Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P & Chiosis G (2004) Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 11, 787797.
  • 44
    Zhou DTF, Liu Y, Ye J, Ying W, Shin Ogawa L, Inoue T, Lee W, Adjiri-Awere A, Kolodzieyski L, Tatsuta N, et al. (2012) Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors. J Clin Oncol 30, suppl. 3086.
  • 45
    Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF & Burrows LCFFJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407410.
  • 46
    Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, et al. (2011) Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 7, 818826.
  • 47
    Hughes PF, Barrott JJ, Carlson DA, Loiselle DR, Speer BL, Bodoor K, Rund LA & Haystead TA (2012) A highly selective Hsp90 affinity chromatography resin with a cleavable linker. Bioorg Med Chem 20, 32983305.
  • 48
    Li Y, Zhang T, Schwartz SJ & Sun D (2009) New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updates 12, 1727.
  • 49
    Powers MV & Workman P (2007) Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 581, 37583769.
  • 50
    Chiosis G, Caldas Lopes E & Solit D (2006) Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr Opin Invest Drugs 7, 534541.
  • 51
    Workman P, Burrows F, Neckers L & Rosen N (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 1113, 202216.
  • 52
    Neckers L & Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18, 6476.
  • 53
    Trepel J, Mollapour M, Giaccone G & Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10, 537549.
  • 54
    Welch WJ & Feramisco JR (1982) Purification of the major mammalian heat shock proteins. J Biol Chem 257, 1494914959.
  • 55
    Sahu D, Zhao Z, Tsen F, Cheng CF, Park R, Situ AJ, Dai J, Eginli A, Shams S, Chen M, et al. (2012) A potentially common peptide target in secreted heat shock protein-90alpha for hypoxia-inducible factor-1alpha-positive tumors. Mol Biol Cell 23, 602613.
  • 56
    Whitesell L & Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5, 761772.
  • 57
    Zagouri F, Sergentanis TN, Nonni A, Papadimitriou CA, Michalopoulos NV, Domeyer P, Theodoropoulos G, Lazaris A, Patsouris E, Zogafos E, et al. (2010) Hsp90 in the continuum of breast ductal carcinogenesis: evaluation in precursors, preinvasive and ductal carcinoma lesions. BMC Cancer 10, 353.
  • 58
    Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL & Kluger HM (2007) High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67, 29322937.
  • 59
    Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL & Lyerly HK (2012) Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res 14, R62.
  • 60
    Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, Stolz W & Vogt T (2004) Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 13, 2732.
  • 61
    Flandrin P, Guyotat D, Duval A, Cornillon J, Tavernier E, Nadal N & Campos L (2008) Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 13, 357364.
  • 62
    Kubota H, Yamamoto S, Itoh E, Abe Y, Nakamura A, Izumi Y, Okada H, Iida M, Nanjo H, Itoh H, et al. (2010) Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma. Cell Stress Chaperones 15, 10031011.
  • 63
    Burgess EF, Ham AJ, Tabb DL, Billheimer D, Roth BJ, Chang SS, Cookson MS, Hinton TJ, Cheek KL, Hill S, et al. (2008) Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes. Proteomics Clin Appl 2, 1223.
  • 64
    Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ & Hirschowitz EA (2003) Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev 27, 285290.
  • 65
    Li W, Sahu D & Tsen F (2012) Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. Biochim Biophys Acta 1823, 730741.
  • 66
    Samant RS, Clarke PA & Workman P (2012) The expanding proteome of the molecular chaperone HSP90. Cell Cycle 11, 13011308.
  • 67
    Prince T & Neckers L (2011) A network of its own: the unique interactome of the Hsp90 cochaperone, Sba1/p23. Mol Cell 43, 159160.
  • 68
    Echeverria PC, Bernthaler A, Dupuis P, Mayer B & Picard D (2011) An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine. PLoS ONE 6, e26044.
  • 69
    Sidera K & Patsavoudi E (2008) Extracellular HSP90: conquering the cell surface. Cell Cycle 7, 15641568.
  • 70
    Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, et al. (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6, 507514.
  • 71
    Tsutsumi S & Neckers L (2007) Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 98, 15361539.
  • 72
    Cheng CF, Fan J, Fedesco M, Guan S, Li Y, Bandyopadhyay B, Bright AM, Yerushalmi D, Liang M, Chen M, et al. (2008) Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing. Mol Cell Biol 28, 33443358.
  • 73
    Li W, Li Y, Guan S, Fan J, Cheng CF, Bright AM, Chinn C, Chen M & Woodley DT (2007) Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J 26, 12211233.
  • 74
    Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J, Atadja P & Bhalla K (2008) Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 68, 48334842.
  • 75
    Quanz M, Herbette A, Sayarath M, de Koning L, Dubois T, Sun JS & Dutreix M (2012) Heat shock protein 90alpha (Hsp90alpha) is phosphorylated in response to DNA damage and accumulates in repair foci. J Biol Chem 287, 88038815.
  • 76
    Ullrich SJ, Robinson EA, Law LW, Willingham M & Appella E (1986) A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Nat Acad Sci USA 83, 31213125.
  • 77
    Sidera K, Samiotaki M, Yfanti E, Panayotou G & Patsavoudi E (2004) Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J Biol Chem 279, 4537945388.
  • 78
    Saito K, Dai Y & Ohtsuka K (2005) Enhanced expression of heat shock proteins in gradually dying cells and their release from necrotically dead cells. Exp Cell Res 310, 229236.
  • 79
    Yerbury JJ, Stewart EM, Wyatt AR & Wilson MR (2005) Quality control of protein folding in extracellular space. EMBO Rep 6, 11311136.
  • 80
    Sims JD, McCready J & Jay DG (2011) Extracellular heat shock protein (Hsp)70 and Hsp90alpha assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS ONE 6, e18848.
  • 81
    Nickel W (2003) The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur J Biochem/FEBS 270, 21092119.
  • 82
    McCready J, Sims JD, Chan D & Jay DG (2010) Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer 10, 294.
  • 83
    Stellas D, El Hamidieh A & Patsavoudi E (2010) Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11, 51.
  • 84
    Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, Tong M, Chang G & Luo Y (2009) The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci USA 106, 2128821293.
  • 85
    Dowling P, Walsh N & Clynes M (2008) Membrane and membrane-associated proteins involved in the aggressive phenotype displayed by highly invasive cancer cells. Proteomics 8, 40544065.
  • 86
    Taiyab A & Rao ChM (2011) HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion. Biochim Biophys Acta 1813, 213221.
  • 87
    Wong K, Koczywas M, Goldman JW, Paschold EH, Horn L, Lufkin JM, Blackman RK, Teofilovici F, Shapiro G & Socinski MA (2011) An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 29, suppl. 7500.
  • 88
    Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314, 268274.
  • 89
    Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446, 153158.
  • 90
    Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883892.
  • 91
    Garraway LA & Janne PA (2012) Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2, 214226.
  • 92
    Shimamura T & Shapiro GI (2008) Heat shock protein 90 inhibition in lung cancer. J Thoracic Oncol 3, S152S159.
  • 93
    Holmes JL, Sharp SY, Hobbs S & Workman P (2008) Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 68, 11881197.
  • 94
    Gray PJ Jr, Stevenson MA & Calderwood SK (2007) Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res 67, 1194211950.
  • 95
    McDowell CL, Bryan Sutton R & Obermann WM (2009) Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue. Int J Biol Macromol 45, 310314.
  • 96
    Au Q, Zhang Y, Barber JR, Ng SC & Zhang B (2009) Identification of inhibitors of HSF1 functional activity by high-content target-based screening. J Biomol Screening 14, 11651175.
  • 97
    Dai C, Santagata S, Tang Z, Shi J, Cao J, Kwon H, Bronson RT, Whitesell L & Lindquist S (2012) Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest 122, 37423754.
  • 98
    Schmitt E, Maingret L, Puig PE, Rerole AL, Ghiringhelli F, Hammann A, Solary E, Kroemer G & Garrido C (2006) Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res 66, 41914197.
  • 99
    Carbone DL, Doorn JA, Kiebler Z, Ickes BR & Petersen DR (2005) Modification of heat shock protein 90 by 4-hydroxynonenal in a rat model of chronic alcoholic liver disease. J Pharmacol Experiment Therapeutics 315, 815.
  • 100
    Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, et al. (2007) An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 25, 151159.
  • 101
    Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB & Yao TP (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18, 601607.
  • 102
    Murphy PJ, Morishima Y, Kovacs JJ, Yao TP & Pratt WB (2005) Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J Biol Chem 280, 3379233799.
  • 103
    Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et al. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280, 2672926734.
  • 104
    Kekatpure VD, Dannenberg AJ & Subbaramaiah K (2009) HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 284, 74367445.
  • 105
    Wandinger SK, Suhre MH, Wegele H & Buchner J (2006) The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J 25, 367376.
  • 106
    Duval M, Le Boeuf F, Huot J & Gratton JP (2007) Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell 18, 46594668.
  • 107
    Kurokawa M, Zhao C, Reya T & Kornbluth S (2008) Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. Mol Cell Biol 28, 54945506.
  • 108
    Lees-Miller SP & Anderson CW (1989) Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II. J Biol Chem 264, 24312437.
  • 109
    Mollapour M, Tsutsumi S & Neckers L (2010) Hsp90 phosphorylation, Wee1 and the cell cycle. Cell Cycle 9, 23102316.
  • 110
    Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, et al. (2010) Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell 37, 333343.
  • 111
    Mollapour M, Tsutsumi S, Truman AW, Xu W, Vaughan CK, Beebe K, Konstantinova A, Vourganti S, Panaretou B, Piper PW, et al. (2011) Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol Cell 41, 672681.
  • 112
    Mollapour M, Tsutsumi S, Kim YS, Trepel J & Neckers L (2011) Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget 2, 407417.
  • 113
    Xu W, Mollapour M, Prodromou C, Wang S, Scroggins BT, Palchick Z, Beebe K, Siderius M, Lee MJ, Couvillon A, et al. (2012) Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine. Mol Cell 47, 434443.
  • 114
    Lees-Miller SP & Anderson CW (1989) The human double-stranded DNA-activated protein kinase phosphorylates the 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal threonine residues. J Biol Chem 264, 1727517280.
  • 115
    Adinolfi E, Kim M, Young MT, Di Virgilio F & Surprenant A (2003) Tyrosine phosphorylation of HSP90 within the P2X7 receptor complex negatively regulates P2X7 receptors. J Biol Chem 278, 3734437351.
  • 116
    Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115131.
  • 117
    Huang SY, Tsai ML, Chen GY, Wu CJ & Chen SH (2007) A systematic MS-based approach for identifying in vitro substrates of PKA and PKG in rat uteri. J Proteome Res 6, 26742684.
  • 118
    Lei H, Venkatakrishnan A, Yu S & Kazlauskas A (2007) Protein kinase A-dependent translocation of Hsp90 alpha impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J Biol Chem 282, 93649371.
  • 119
    Martinez-Ruiz A, Villanueva L, Gonzalez de Orduna C, Lopez-Ferrer D, Higueras MA, Tarin C, Rodriguez-Crespo I, Vazquez J & Lamas S (2005) S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Nat Acad Sci USA 102, 85258530.
  • 120
    Retzlaff M, Stahl M, Eberl HC, Lagleder S, Beck J, Kessler H & Buchner J (2009) Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep 10, 11471153.
  • 121
    Blank M, Mandel M, Keisari Y, Meruelo D & Lavie G (2003) Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res 63, 82418247.